PET-response adapted clinical trials
51 slide(s) – 00:27:22 – English – 2010-06-11
People attending the session and interested to the presented issues should be informed that interim-PET in lymphoma is one of the most powerful predictor of treatment outcome. However, interpretation rules for interim-PET scan are different from the ones used for end-treatment scan evaluation, and cepted criteria are still unsettled. For these reasons people attending the session will be incouraged (a) to participate to international workshops in interim-PET in lymphoma (the next is scheduled in Menton (French riviera) for October 2011) (b) to enroll patients in clinical trials adpting a therapeutic strategyu PET-response adapted. Moreover, people should realize that interim-PET scan could not be used at this moment in the daily clinical practice until the International Validation Studies to validate the proposed rules for interim PET reporting in Hodghkin lymphoma and Diffuse Aggressive B-Cell lymphoma will be not accomplished.